...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model
【24h】

Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model

机译:万古霉素从聚氨酯支架中持续释放可抑制大鼠股骨节段缺损模型中骨伤口的感染

获取原文
获取原文并翻译 | 示例
           

摘要

Infection is a common complication in open fractures that compromises the healing of bone and can result in loss of limb or life. Currently, the clinical standard of care for treating contaminated open fractures comprises a staged approach, wherein the wound is first treated with non-biodegradable antibiotic-laden poly(methyl methacrylate) (PMMA) beads to control the infection followed by bone grafting. Considering that tissue regeneration is associated with new blood vessel formation, which takes up to 6. weeks in segmental defects, a biodegradable bone graft with sustained release of an antibiotic is desired to prevent the implant from becoming infected, thus allowing the processes of both vascularization and new bone formation to occur unimpeded. In the present study, we utilized biodegradable porous polyurethane (PUR) scaffolds as the delivery vehicle for vancomycin. Hydrophobic vancomycin free base (V-FB) was obtained by precipitating the hydrophilic vancomycin hydrochloride (V-HCl) at pH 8. The decreased solubility of V-FB resulted in an extended vancomycin release profile . in vitro, as evidenced by the fact that active vancomycin was released for up to 8. weeks at concentrations well above both the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC). Using PUR prepared from lysine triisocyanate (LTI) (PUR(LTI)), the extended . in vitro release profile observed for V-FB translated to improved infection control . in vivo compared to V-HCl in a contaminated critical-sized fat femoral segmental defect. The performance of PUR(LTI)/V-FB was comparable to PMMA/V-HCl beads . in vivo. However, compared with PMMA, PUR is a biodegradable system which does not require the extra surgical removal step in clinical use. These results suggest that PUR scaffolds incorporating V-FB could be a potential clinical therapy for treatment of infected bone defects.
机译:感染是开放性骨折的常见并发症,会损害骨骼的愈合,并可能导致肢体或生命损失。当前,治疗受污染的开放性骨折的临床护理标准包括分阶段进行的方法,其中首先用不可生物降解的载有抗生素的聚甲基丙烯酸甲酯(PMMA)珠粒治疗伤口,以控制感染,然后进行植骨。考虑到组织再生与新血管的形成有关,该新血管的形成需要长达6周的节段性缺损,因此需要一种生物可降解的骨移植物并持续释放抗生素,以防止植入物被感染,从而使两种血管形成过程和新的骨形成不受阻碍地发生。在本研究中,我们利用可生物降解的多孔聚氨酯(PUR)支架作为万古霉素的递送载体。疏水性万古霉素游离碱(V-FB)是通过在pH 8处沉淀亲水性万古霉素盐酸盐(V-HCl)获得的。V-FB溶解度降低导致万古霉素释放曲线延长。在体外,活性万古霉素在远高于最小抑菌浓度(MIC)和最小杀菌浓度(MBC)的浓度下释放长达8周。使用由赖氨酸三异氰酸酯(LTI)(PUR(LTI))制备的PUR,扩展了。观察到V-FB的体外释放曲线可改善感染控制。体内与V-HCl相比在受污染的临界大小的脂肪股节段性缺损中具有优势。 PUR(LTI)/ V-FB的性能可与PMMA / V-HCl珠相媲美。体内。但是,与PMMA相比,PUR是一种可生物降解的系统,在临床使用中不需要额外的手术移除步骤。这些结果表明,结合了V-FB的PUR支架可能是治疗感染的骨缺损的潜在临床疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号